Epidural Hydromorphone for Postpartum Pain Management After Vaginal DeliveryA Randomized Clinical Trial

This single-center randomized controlled trial (RCT) evaluated the efficacy and safety of low-dose epidural hydromorphone (0.5 mg) for postpartum pain management following vaginal delivery. A total of 450 full-term pregnant women were randomized into two groups: the hydromorphone group (HY group, n=221) and the normal saline control group (NS group, n=222). The primary outcome was pain intensity within 48 hours postpartum, while secondary outcomes included adverse events, supplemental analgesic requirements, and patient satisfaction.Key Findings:Significant Pain ReductionThe HY group demonstrated significantly lower pain scores at all assessed time points (4, 8, 12, 16, 24, and 48 hours postpartum; P < 0.001).The incidence of pain decreased from 88.29% in the NS group to 49.77% in the HY group (OR 7.61, 95% CI 4.68–12.38).Mixed pain (e.g., perineal pain combined with uterine cramping) was markedly reduced in the HY group (9.95% vs. 38.29% in the NS group).Safety and Adverse EventsThe HY group had higher rates of nausea/vomiting (26.2% vs. 8.1%), pruritus (32.6% vs. 7.2%), and urinary retention (20.8% vs. 7.7%), but these side effects were generally transient and manageable.The NS group reported significantly more insomnia (30.2% vs. 5.4%), highlighting the impact of uncontrolled pain on quality of life.Clinical ImplicationsEpidural hydromorphone delayed the time to first rescue analgesia by 3.63 hours (95% CI 0.59–6.66; P = 0.02) and reduced the need for supplemental analgesics (OR 3.31, 95% CI 2.02–5.41).Patient satisfaction with pain relief was significantly higher in the HY group (95.93% vs. 69.37%; P < 0.001).Conclusion:Epidural hydromorphone (0.5 mg) is an effective strategy for acute postpartum pain relief after vaginal delivery, though clinicians must weigh its benefits against transient side effects. This approach offers a promising option for enhancing maternal recovery and early mobilization.